Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA
Longer term follow-up data will be presented from the pivotal CARTITUDE-1 study in patients with relapsed or refractory multiple myeloma, which supported the recent U.S. FDA approval of CARVYKTI
United States New Jersey Ciltacabtagene Autoleucel Hemophagocytic Lymphohistiocytosis Joanne Choi Ying Huang
Source: finanznachrichten.de